Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023.

The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023.

A live webcast of the call will be available via this link or on the Investors section of Morphic’s website, at www.morphictx.com. An archived replay will be available on the company’s website following the conference call. To join the question-and-answer queue on the live conference call, please click here to register and receive a personalized dial in number.

About MORF-057
Morphic is developing MORF-057 as a selective, oral small molecule inhibitor of the α4β7 integrin for patients with inflammatory bowel disease (IBD). α4β7 has been clinically validated as a target for the treatment of IBD by the success of the approved injectable antibody therapeutic vedolizumab. MORF-057, like vedolizumab, is designed to block the interactions between α4β7 on the surface of lymphocytes and the mucosal endothelial cell ligand MAdCAM-1, substantially reducing lymphocyte migration from the bloodstream into intestinal mucosal tissues and avoiding inflammation that is associated with IBD.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contact
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Staff

Recent Posts

Therma Bright Q2, 2024 Market Update On Business

Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by…

42 mins ago

Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences

The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…

2 hours ago

High-Growth Industries with 25%-30% CAGR Growth Over the Next Five Years

BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…

2 hours ago

Bioz Brings Cutting-Edge AI Citation Widgets to Precision X-Ray, Inc.’s Product Pages

PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…

2 hours ago

iZafe Group Receives Confirmed Order of 500 Dosell Units from Ti Medi

STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…

2 hours ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…

5 hours ago